ReproCELL Incorporated (TYO:4978)
Japan
· Delayed Price · Currency is JPY 171.00
-1.00 (-0.58%)
Jun 26, 2025, 1:41 PM JST
ReproCELL Revenue
In the fiscal year ending March 31, 2025, ReproCELL had annual revenue of 2.98B JPY with 22.75% growth. ReproCELL had revenue of 910.00M in the quarter ending March 31, 2025, with 40.00% growth.
Revenue
2.98B
Revenue Growth
+22.75%
P/S Ratio
5.47
Revenue / Employee
31.02M
Employees
96
Market Cap
16.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.98B | 552.00M | 22.75% |
| Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
| Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
| Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
| Mar 31, 2021 | 1.29B | 87.00M | 7.26% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.30B |